GlassScriptPhysician profile
Michael B Evan
NPI 1336123124
$4,348.95
in general payments reported to CMS, 2019-2025
49 companies · $579 in 2025
The $579 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $521 · 2021: $578 · 2022: $1,038 · 2023: $731 · 2024: $441 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,751.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $812.96 | 2020-2025 | |
| Amgen INC. | $318.30 | 2019-2025 | Repatha, Otezla, Prolia |
| Teva Pharmaceuticals USA, INC. | $316.49 | 2019-2023 | Ajovy |
| Novo Nordisk INC | $306.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $305.99 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $181.27 | 2019-2024 | Verquvo, Belsomra, Dificid |
| Bayer Healthcare Pharmaceuticals INC. | $178.45 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.60 | 2020-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $166.28 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $161.64 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $147.55 | 2019-2025 | Airsupra, Farxiga |
| Abbott Laboratories | $137.75 | 2019-2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $78.18 | 2020-2023 | |
| Shield Therapeutics INC | $72.50 | 2023-2025 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $66.59 | 2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Evan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.